Management

Eric A. Adams, MIBS

Chief Executive Officer & President

Eric A. Adams was appointed Chief Executive Officer, President and Director of InMed Pharmaceuticals, Inc. in June 2016. During his tenure at InMed, he has reconstituted the Board of Directors and the Executive management team and has raised more than $35M in

capital to fund operations. Mr. Adams is a seasoned biopharmaceutical executive with over 25 years’ experience in establishing corporate entities, capital formation, global market development, mergers & acquisitions, licensing and corporate governance.

Mr. Adams previously served as CEO at enGene Inc., where he oversaw its transformation from a nascent start-up into a venture capital-backed leader in gene therapy. Prior to enGene, Mr. Adams held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL), and Fresenius AG (Germany). As the previous Chairman of BIOTECanada’s Emerging Company Advisory Board, and for his extensive generosity in mentoring biotech entrepreneurs, Mr. Adams is well respected within the Canadian biotech industry as a strategic advisor to a number of early-stage biotech companies.

He is a dual citizen of Canada and the United States, and holds a Masters of International Business from the University of South Carolina and a Bachelor’s Degree in Chemistry from the University of Southern Indiana.
Learn More

Jeff Charpentier, CPA, CA

Chief Financial Officer

Mr. Charpentier is a veteran of the biopharmaceutical industry with 26 years of experience. Mr. Charpentier has held a series of senior financial roles at several public and private companies in the pharmaceutical and technology sectors. Mr. Charpentier has

been our Chief Financial Officer and Corporate Secretary since December, 2016.

Mr. Charpentier also currently serves as CFO for ImStar Therapeutics Inc. and Proactive Immune Sciences Corporation. Mr. Charpentier previously served as CFO for Lifebank Corp. (through to successful company sale in 2012), Inex Pharmaceuticals Corporation (now Arbutus Biopharma Corp.), and Chromos Molecular Systems Inc.

Mr. Charpentier has a Bachelor of Commerce degree from the University of British Columbia and is a member of the Chartered Professional Accountants of BC.
Learn More

Josh Blacher, MBA

Chief Business Officer

Mr. Blacher brings two decades of leadership experience in senior positions within the US healthcare and capital markets sectors, focusing primarily on strategic finance, business development, and managing relations with the investment community.


Mr. Blacher has been our Chief Business Officer since April, 2018. Before joining InMed, Mr. Blacher served as Chief Financial Officer at Therapix Biosciences and Galmed Pharmaceuticals. Mr. Blacher also held senior positions in licensing and investing at Teva Pharmaceuticals, portfolio management at Deutsche Asset Management and equity research at Morgan Stanley, as well as in Mergers & Acquisitions at Lehman Brothers.

Mr. Blacher holds an MBA in Finance from Columbia Business School.
Learn More

Alexandra D.J. Mancini, MSc

Senior Vice President, Clinical & Regulatory Affairs

Ms. Mancini has over 30 years of global biopharmaceutical R&D experience, overseeing a wide range of drug development activities, with a particular emphasis on clinical development and regulatory affairs. She has been an executive with numerous biotech

companies, including Snr. V.P. of Clinical & Regulatory Affairs at Sirius Genomics, where her responsibilities included identifying and managing external resources for medical expertise in sepsis; clinical data management; and statistical theory, programming and analyses.

Prior to joining Sirius Genomics, Ms. Mancini served as Sr. V.P. of Clinical & Regulatory Affairs at INMEX Pharmaceuticals; and V.P. of Regulatory Affairs at QLT Inc., where she played a significant role in the development of VISUDYNE from the preclinical stage through to its approval as the first drug for age-related macular degeneration. While at QLT, Ms. Mancini also led the regulatory approval process for the anti-cancer drug PHOTOFRIN and its associated medical devices; the first drug-device combination product approved by the US Food and Drug Administration.

Ms. Mancini holds a Master of Science degree from the University of Toronto. She is also a Visiting Lecturer at the Segal Graduate School of Business, Simon Fraser University.
Learn More

Eric C. Hsu, PhD

Senior Vice President, Pre-Clinical Research & Development

Dr. Hsu joined InMed with over 18 years of scientific leadership experience in the field of gene therapy. Prior to joining InMed, he held various positions within enGene Inc., including V.P. of Research and V.P. of Scientific Affair and

Operations.

His experience includes a wide array of activities, including benchtop research, formulation development and manufacturing process development, as well as patent prosecution, vendor contract negotiations and execution, and research partnerships. He is also responsible for expanding product pipelines, and managing R&D budgets and timelines. Dr. Hsu is considered to be an expert in gene transfer and gene expression using vector systems.

Dr. Hsu received his Doctorate from the Department of Medical Biophysics at University of Toronto and his Bachelor’s degree from McGill University.
Learn More

Michael Woudenberg, P.Eng.

Vice President, Chemistry, Manufacturing & Controls

Mr. Woudenberg joined InMed with over 20 years of engineering, leadership and GMP manufacturing and scale up experience with regards to the development, technology transfer and commercialization of active pharmaceutical ingredients (APIs) and drug products. He

has been our Vice President, Chemistry Manufacturing and Control since November, 2018. Prior to joining InMed, Mr. Woudenberg held various positions within 3M, Cardiome Pharma, Arbutus Biopharma and most recently as the Managing Director of Phyton Biotech, LLC.

His experience includes process and formulation development from lab / pre-clinical products through the various stages of clinical development to validated and successfully approved and inspected commercial APIs and drug products. Additionally, he has extensive experience with regards to regulatory inspections (e.g. FDA, European, Australian, Korean, Japanese, Canadian) and their related chemistry, manufacturing and control requirements from clinical to commercial production of approved products.

Mr. Woudenberg received his Bachelor’s of Science, Chemistry and Bachelors of Engineering Science, Chemical at Western University of London, Ontario, Canada.
Learn More

Overview

Board of Directors

Scientific Advisory Board

Stay up to Date​

Subscribe to all of our investor information, including news, events, presentations and more